Verfügbarkeit: Expanding access to investigational therapies for HIV infection and AIDS :

Expanding access to investigational therapies for HIV infection and AIDS :: March 12-13, 1990, conference summary /

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Nichols, Eve K.
Körperschaft:	Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine)
Format:	Elektronisch E-Book
Sprache:	English
Veröffentlicht:	Washington, D.C. : National Academy Press, 1991.
Schlagworte:	AIDS (Disease) > Chemotherapy > Social aspects > United States > Congresses. Pharmacology, Experimental > Social aspects > United States > Congresses. HIV infections > Chemotherapy > Social aspects > United States > Congresses. Institutional review boards (Medicine) Health services accessibility. Social control. AIDS (Disease) Children. Federal government. Human experimentation in medicine. Research. Risk. HIV infections. Risk assessment. Ethics committees. Liberty. Information services. Women. Medical care. Informed consent (Medical law) Minorities. Pharmaceutical industry. Methodology. Economics. Human rights. Sociology. Probabilities. Industries. Slow virus diseases. Non-governmental organizations. Science. National health services. Drugs. Health services administration. Communication. Immunological deficiency syndromes. Risk management. Lentivirus infections. Social sciences. Insurance. Therapeutics. Medical care > Quality control. Statistics. Public health. Physical sciences. Humanities. Sexually transmitted diseases. Virus diseases. Misinformation. Ethics Committees, Research Government Regulation Health Services Accessibility Personal Autonomy Public Policy Random Allocation Research Design Social Control, Formal HIV Seropositivity Acquired Immunodeficiency Syndrome Child Federal Government Human Experimentation Information Dissemination Patient Selection Research Risk Socioeconomic Factors Government HIV Infections Insurance, Health Risk Assessment Ethics Committees Freedom Information Services Therapeutic Human Experimentation Women Clinical Trials as Topic Patient Care Vulnerable Populations Informed Consent Research Subjects Minority Groups Drugs, Investigational Drug Industry Financial Support Health Care Economics and Organizations Methods Economics Human Rights Sociology Probability Industry Principle-Based Ethics Slow Virus Diseases Ethics Epidemiologic Study Characteristics as Topic Professional Staff Committees Organizations Evaluation Studies as Topic Psychological Phenomena and Processes Jurisprudence Social Control Policies Delivery of Health Care Patient Rights Science Persons Health Services Epidemiologic Research Design Pharmaceutical Preparations Patient Care Management Population Characteristics Communication Age Groups Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Risk Management Epidemiologic Measurements Lentivirus Infections Social Sciences Information Science Biomedical Research Insurance Investigative Techniques Therapeutics Health Care Quality, Access, and Evaluation Quality Assurance, Health Care Technology, Industry, and Agriculture Statistics as Topic Professional Practice Public Health Natural Science Disciplines Health Care Evaluation Mechanisms Named Groups Financing, Organized Humanities Sexually Transmitted Diseases Chemicals and Drugs Epidemiologic Methods Virus Diseases Policy Psychiatry and Psychology Médicaments contre le sida > Aspect social > États-Unis > Congrès. Pharmacologie expérimentale > Aspect social > États-Unis > Congrès. Infections à VIH > Chimiothérapie > Aspect social > États-Unis > Congrès. Comités d'éthique de la recherche. Services de santé > Accessibilité. Contrôle social. Sida. Enfants. Gouvernement fédéral. Expérimentation humaine en médecine. Sélection de patients. Recherche. Risque. Institutions politiques. Infections à VIH. Assurance-maladie. Évaluation du risque. Comités d'éthique. Liberté. Services d'information. Femmes. Soins médicaux. Consentement éclairé (Droit médical) Minorités. Industrie pharmaceutique. Méthodologie. Économie politique. Droits de l'homme (Droit international) Sociologie. Probabilités. Industrie. Maladies à virus lents. Organisations non gouvernementales. Prestation de soins. Sciences. Services de santé. Médicaments. Services de santé > Administration. Syndromes de déficit immunitaire. Gestion du risque. Infections à lentivirus. Sciences sociales. Assurance. Thérapeutique. Soins médicaux > Qualité > Contrôle. Statistiques. Pratique professionnelle. Santé publique. Sciences physiques. Sciences humaines. Infections transmissibles sexuellement. Maladies à virus. Information. Statistique. Mésinformation. children (people by age group) federal government. research (function) governments (administrative bodies) risk assessment. freedom. minorities. methodology. economics. sociology. probability. sciences (philosophy) risk management. social sciences. insurance. public health. physical sciences. humanities. women (female humans) science (modern discipline) treating (health care function) statistics. MEDICAL > AIDS & HIV. HEALTH & FITNESS > Diseases > AIDS & HIV. Pharmacology, Experimental > Social aspects Syndrome d'immunodéficience acquise. United States AIDS > Chemotherapy > Social > United > Congresses HIV > Chemotherapy > Social > United > Congresses Pharmacology, > Social > United > Congresses Congress proceedings (reports) Conference papers and proceedings Conference papers and proceedings. Actes de congrès.
Online-Zugang:	Volltext
Beschreibung:	1 online resource (viii, 73 pages)
Format:	Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
Bibliographie:	Includes bibliographical references.
ISBN:	058515547X 9780585155470

Internformat

MARC


LEADER	00000cam a2200000 a 4500
001	ZDB-4-EBA-ocn559734779
003	OCoLC
005	20241004212047.0
006	m o d
007	cr cn\|\|\|\|\|\|\|\|\|
008	910211s1991 dcu ob 100 0 eng d
040			\|a MERUC \|b eng \|e pn \|c MERUC \|d CCO \|d E7B \|d OCLCQ \|d UV0 \|d CASUM \|d DKDLA \|d OCLCE \|d IDEBK \|d CUS \|d XFF \|d OCLCQ \|d ORU \|d OCLCQ \|d N$T \|d YDXCP \|d COF \|d OCLCO \|d FVL \|d OCLCQ \|d NLGGC \|d OCLCO \|d OCLCQ \|d OCLCO \|d OCLCQ \|d AZK \|d TOA \|d COCUF \|d AGLDB \|d MNU \|d SUR \|d MOR \|d PIFBR \|d OCLCQ \|d OCLCA \|d U3W \|d OCLCA \|d BUF \|d OCLCO \|d GILDS \|d OCLCF \|d OCLCO \|d VNS \|d OCLCO \|d OCLCQ \|d VTS \|d LVT \|d VT2 \|d STF \|d WRM \|d NRAMU \|d INT \|d XFH \|d EBLCP \|d ZCU \|d ICG \|d OCLCQ \|d N$T \|d OCLCO \|d AU@ \|d OCLCQ \|d OCLCO \|d OCLCA \|d DKC \|d OCLCO \|d OCLCQ \|d ADU \|d KIJ \|d OCLCA \|d INARC \|d AJS \|d OCLCA \|d OCLCO \|d OCLCQ \|d OCLCO \|d OCLCL \|d OCLCQ
019			\|a 44954780 \|a 228064206 \|a 245535671 \|a 475709283 \|a 551505442 \|a 629930493 \|a 642456878 \|a 647353775 \|a 666933634 \|a 722242379 \|a 728013566 \|a 814274466 \|a 923259948 \|a 961669896 \|a 961673586 \|a 962592044 \|a 962635940 \|a 972040095 \|a 975242794 \|a 975293706 \|a 982314368 \|a 984884368 \|a 988438325 \|a 990088987 \|a 992114622 \|a 994555841 \|a 1003586155 \|a 1016139292 \|a 1017678387 \|a 1018073288 \|a 1021259647 \|a 1058117548 \|a 1112848367 \|a 1118983063 \|a 1119024608 \|a 1156404089 \|a 1162131089 \|a 1175669579 \|a 1182015092 \|a 1193130606 \|a 1204385213 \|a 1228541956 \|a 1424845104
020			\|a 058515547X \|q (electronic bk.)
020			\|a 9780585155470 \|q (electronic bk.)
020			\|z 1280203560
020			\|z 9781280203565
020			\|z 9780309583367
020			\|z 0309583365
020			\|z 0309044901 \|q (pbk.)
020			\|z 9780309044905 \|q (pbk.)
035			\|a (OCoLC)559734779 \|z (OCoLC)44954780 \|z (OCoLC)228064206 \|z (OCoLC)245535671 \|z (OCoLC)475709283 \|z (OCoLC)551505442 \|z (OCoLC)629930493 \|z (OCoLC)642456878 \|z (OCoLC)647353775 \|z (OCoLC)666933634 \|z (OCoLC)722242379 \|z (OCoLC)728013566 \|z (OCoLC)814274466 \|z (OCoLC)923259948 \|z (OCoLC)961669896 \|z (OCoLC)961673586 \|z (OCoLC)962592044 \|z (OCoLC)962635940 \|z (OCoLC)972040095 \|z (OCoLC)975242794 \|z (OCoLC)975293706 \|z (OCoLC)982314368 \|z (OCoLC)984884368 \|z (OCoLC)988438325 \|z (OCoLC)990088987 \|z (OCoLC)992114622 \|z (OCoLC)994555841 \|z (OCoLC)1003586155 \|z (OCoLC)1016139292 \|z (OCoLC)1017678387 \|z (OCoLC)1018073288 \|z (OCoLC)1021259647 \|z (OCoLC)1058117548 \|z (OCoLC)1112848367 \|z (OCoLC)1118983063 \|z (OCoLC)1119024608 \|z (OCoLC)1156404089 \|z (OCoLC)1162131089 \|z (OCoLC)1175669579 \|z (OCoLC)1182015092 \|z (OCoLC)1193130606 \|z (OCoLC)1204385213 \|z (OCoLC)1228541956 \|z (OCoLC)1424845104
042			\|a dlr
043			\|a n-us---
050		4	\|a RC607.A26 \|b N53 1991eb
060		4	\|a WD 308 \|b N617e 1991
072		7	\|a MED \|x 022020 \|2 bisacsh
072		7	\|a HEA \|x 039020 \|2 bisacsh
072		7	\|a MJCJ2 \|2 bicssc
082	7		\|a 362.1/969792/00973 \|2 20
084			\|a 44.38 \|2 bcl
084			\|a 44.75 \|2 bcl
084			\|a GV 90(A1) \|2 blsrissc
084			\|a HE 66 \|2 blsrissc
084			\|a HE 60 \|2 blsrissc
049			\|a MAIN
100	1		\|a Nichols, Eve K. \|0 http://id.loc.gov/authorities/names/n86137599
245	1	0	\|a Expanding access to investigational therapies for HIV infection and AIDS : \|b March 12-13, 1990, conference summary / \|c Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.
260			\|a Washington, D.C. : \|b National Academy Press, \|c 1991.
300			\|a 1 online resource (viii, 73 pages)
336			\|a text \|b txt \|2 rdacontent
337			\|a computer \|b c \|2 rdamedia
338			\|a online resource \|b cr \|2 rdacarrier
347			\|a data file
504			\|a Includes bibliographical references.
588	0		\|a Print version record.
506			\|3 Use copy \|f Restrictions unspecified \|5 MiAaHDL \|2 star
533			\|a Electronic reproduction. \|b [Place of publication not identified] : \|c HathiTrust Digital Library, \|d 2010. \|5 MiAaHDL
538			\|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. \|u http://purl.oclc.org/DLF/benchrepro0212 \|5 MiAaHDL
583	1		\|a digitized \|c 2010 \|h HathiTrust Digital Library \|l committed to preserve \|5 MiAaHDL \|2 pda
505	0		\|a ""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12â€?13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development""
505	8		\|a Improving Response CapabilitiesExpedited Development -- Expanded Access -- Treatment Investigational New Drugs -- Parallel Track -- 2 RIGHTS AND RESPONSIBILITIES -- FREEDOM OF CHOICE -- INFORMED CONSENT -- Information Resources -- Access -- Primary Care -- Difficult Choices -- COMPETING RIGHTS -- INSTITUTIONAL REVIEW BOARDS -- NEW ATTITUDES -- 3 EVALUATION OF EXPANDED ACCESS PROGRAMS -- TREATMENT INVESTIGATIONAL NEW DRUGS -- POTENTIAL RISKS -- Examples from the Past -- The Target Population -- Safety Data
505	8		\|a IMPACT ON CONVENTIONAL RANDOMIZED TRIALSTHE PARALLEL TRACK EXPERIMENT -- 4 CREATIVITY IN CLINICAL TRIALS -- THE CHANGING ENVIRONMENT -- CONVENTIONAL TRIALS -- PREFERENCE TRIALS -- LARGE, SIMPLE RANDOMIZED TRIALS -- Physician Participation -- Quality Control -- DATA FROM THE PARALLEL TRACK -- Efficacy Data -- Safety Data and Related Information -- Expectations -- 5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY -- TIME TO COMMERCIALIZATION -- DIRECT COSTS OF EXPANDED ACCESS -- Manpower Needs -- Drug Costs -- The Small Manufacturer
505	8		\|a PRODUCT LIABILITYConcerns Specific to the Parallel Track -- Potential Solutions -- 6 THIRD-PARTY PAYERS -- BLUE CROSS AND BLUE SHIELD -- HEALTH INSURANCE ASSOCIATION OF AMERICA -- HEALTH CARE FINANCING ADMINISTRATION -- Medicaid -- State Discretion -- Patient Care Costs -- Medicare -- RESOURCES FOR CLINICAL INVESTIGATION -- 7 IMPROVING ACCESS TO CARE -- PEOPLE OF COLOR -- Resource Considerations -- Suspicion -- Informed Consent -- WOMEN -- The Gender Perspective -- Risk Factors -- Protocol Development -- Women as Vectors -- A New Approach
505	8		\|a THE PEDIATRIC POPULATIONScientific Issues -- Social Issues
546			\|a English.
650		0	\|a AIDS (Disease) \|x Chemotherapy \|x Social aspects \|z United States \|v Congresses.
650		0	\|a Pharmacology, Experimental \|x Social aspects \|z United States \|v Congresses.
650		0	\|a HIV infections \|x Chemotherapy \|x Social aspects \|z United States \|v Congresses.
650		0	\|a Institutional review boards (Medicine) \|0 http://id.loc.gov/authorities/subjects/sh2001010894
650		0	\|a Health services accessibility. \|0 http://id.loc.gov/authorities/subjects/sh92006496
650		0	\|a Social control. \|0 http://id.loc.gov/authorities/subjects/sh85123931
650		0	\|a AIDS (Disease) \|0 http://id.loc.gov/authorities/subjects/sh85002541
650		0	\|a Children. \|0 http://id.loc.gov/authorities/subjects/sh85023418
650		0	\|a Federal government. \|0 http://id.loc.gov/authorities/subjects/sh85047611
650		0	\|a Human experimentation in medicine. \|0 http://id.loc.gov/authorities/subjects/sh85062870
650		0	\|a Research. \|0 http://id.loc.gov/authorities/subjects/sh85113021
650		0	\|a Risk. \|0 http://id.loc.gov/authorities/subjects/sh85114195
650		0	\|a HIV infections. \|0 http://id.loc.gov/authorities/subjects/sh91004036
650		0	\|a Risk assessment. \|0 http://id.loc.gov/authorities/subjects/sh87002638
650		0	\|a Ethics committees. \|0 http://id.loc.gov/authorities/subjects/sh85045123
650		0	\|a Liberty. \|0 http://id.loc.gov/authorities/subjects/sh85076480
650		0	\|a Information services. \|0 http://id.loc.gov/authorities/subjects/sh85066157
650		0	\|a Women. \|0 http://id.loc.gov/authorities/subjects/sh85147274
650		0	\|a Medical care. \|0 http://id.loc.gov/authorities/subjects/sh85082871
650		0	\|a Informed consent (Medical law) \|0 http://id.loc.gov/authorities/subjects/sh85066306
650		0	\|a Minorities. \|0 http://id.loc.gov/authorities/subjects/sh85085792
650		0	\|a Pharmaceutical industry. \|0 http://id.loc.gov/authorities/subjects/sh85039713
650		0	\|a Methodology. \|0 http://id.loc.gov/authorities/subjects/sh85084414
650		0	\|a Economics. \|0 http://id.loc.gov/authorities/subjects/sh85040850
650		0	\|a Human rights. \|0 http://id.loc.gov/authorities/subjects/sh85026379
650		0	\|a Sociology. \|0 http://id.loc.gov/authorities/subjects/sh85124200
650		0	\|a Probabilities. \|0 http://id.loc.gov/authorities/subjects/sh85107090
650		0	\|a Industries. \|0 http://id.loc.gov/authorities/subjects/sh85065960
650		0	\|a Slow virus diseases. \|0 http://id.loc.gov/authorities/subjects/sh85143823
650		0	\|a Non-governmental organizations. \|0 http://id.loc.gov/authorities/subjects/sh86007360
650		0	\|a Science. \|0 http://id.loc.gov/authorities/subjects/sh85118553
650		0	\|a National health services. \|0 http://id.loc.gov/authorities/subjects/sh85083180
650		0	\|a Drugs. \|0 http://id.loc.gov/authorities/subjects/sh85039719
650		0	\|a Health services administration. \|0 http://id.loc.gov/authorities/subjects/sh85059600
650		0	\|a Communication. \|0 http://id.loc.gov/authorities/subjects/sh85029027
650		0	\|a Immunological deficiency syndromes. \|0 http://id.loc.gov/authorities/subjects/sh85064574
650		0	\|a Risk management. \|0 http://id.loc.gov/authorities/subjects/sh85114200
650		0	\|a Lentivirus infections. \|0 http://id.loc.gov/authorities/subjects/sh94005194
650		0	\|a Social sciences. \|0 http://id.loc.gov/authorities/subjects/sh85124003
650		0	\|a Insurance. \|0 http://id.loc.gov/authorities/subjects/sh85066802
650		0	\|a Therapeutics. \|0 http://id.loc.gov/authorities/subjects/sh85134723
650		0	\|a Medical care \|x Quality control. \|0 http://id.loc.gov/authorities/subjects/sh85082880
650		0	\|a Statistics. \|0 http://id.loc.gov/authorities/subjects/sh85127580
650		0	\|a Public health. \|0 http://id.loc.gov/authorities/subjects/sh85108638
650		0	\|a Physical sciences. \|0 http://id.loc.gov/authorities/subjects/sh89005705
650		0	\|a Humanities. \|0 http://id.loc.gov/authorities/subjects/sh85062913
650		0	\|a Sexually transmitted diseases. \|0 http://id.loc.gov/authorities/subjects/sh85142634
650		0	\|a Virus diseases. \|0 http://id.loc.gov/authorities/subjects/sh85143818
650		0	\|a Misinformation. \|0 http://id.loc.gov/authorities/subjects/sh2022005564
650		2	\|a Ethics Committees, Research
650		2	\|a Government Regulation
650		2	\|a Health Services Accessibility
650		2	\|a Personal Autonomy
650		2	\|a Public Policy
650		2	\|a Random Allocation
650		2	\|a Research Design
650		2	\|a Social Control, Formal
650		2	\|a HIV Seropositivity
650		2	\|a Acquired Immunodeficiency Syndrome
650		2	\|a Child
650		2	\|a Federal Government
650		2	\|a Human Experimentation
650		2	\|a Information Dissemination
650		2	\|a Patient Selection
650		2	\|a Research
650		2	\|a Risk
650		2	\|a Socioeconomic Factors
650		2	\|a Government
650		2	\|a HIV Infections
650		2	\|a Insurance, Health
650		2	\|a Risk Assessment
650		2	\|a Ethics Committees
650		2	\|a Freedom
650		2	\|a Information Services
650		2	\|a Therapeutic Human Experimentation
650		2	\|a Women
650		2	\|a Clinical Trials as Topic
650		2	\|a Patient Care
650		2	\|a Vulnerable Populations
650		2	\|a Informed Consent
650		2	\|a Research Subjects
650		2	\|a Minority Groups
650		2	\|a Drugs, Investigational
650		2	\|a Drug Industry
650		2	\|a Financial Support
650		2	\|a Health Care Economics and Organizations
650		2	\|a Methods
650		2	\|a Economics
650		2	\|a Human Rights
650		2	\|a Sociology
650		2	\|a Probability
650		2	\|a Industry
650		2	\|a Principle-Based Ethics
650		2	\|a Slow Virus Diseases
650		2	\|a Ethics
650		2	\|a Epidemiologic Study Characteristics as Topic
650		2	\|a Professional Staff Committees
650		2	\|a Organizations
650		2	\|a Evaluation Studies as Topic
650		2	\|a Psychological Phenomena and Processes
650		2	\|a Jurisprudence
650		2	\|a Social Control Policies
650		2	\|a Delivery of Health Care
650		2	\|a Patient Rights
650		2	\|a Science
650		2	\|a Persons
650		2	\|a Health Services
650		2	\|a Epidemiologic Research Design
650		2	\|a Pharmaceutical Preparations
650		2	\|a Patient Care Management
650		2	\|a Population Characteristics
650		2	\|a Communication
650		2	\|a Age Groups
650		2	\|a Sexually Transmitted Diseases, Viral
650		2	\|a Immunologic Deficiency Syndromes
650		2	\|a Risk Management
650		2	\|a Epidemiologic Measurements
650		2	\|a Lentivirus Infections
650		2	\|a Social Sciences
650		2	\|a Information Science
650		2	\|a Biomedical Research
650		2	\|a Insurance
650		2	\|a Investigative Techniques
650		2	\|a Therapeutics
650		2	\|a Health Care Quality, Access, and Evaluation
650		2	\|a Quality Assurance, Health Care
650		2	\|a Technology, Industry, and Agriculture
650		2	\|a Statistics as Topic
650		2	\|a Professional Practice
650		2	\|a Public Health
650		2	\|a Natural Science Disciplines
650		2	\|a Health Care Evaluation Mechanisms
650		2	\|a Named Groups
650		2	\|a Financing, Organized
650		2	\|a Humanities
650		2	\|a Sexually Transmitted Diseases
650		2	\|a Chemicals and Drugs
650		2	\|a Epidemiologic Methods
650		2	\|a Virus Diseases
650		2	\|a Policy
650		2	\|a Psychiatry and Psychology
650		6	\|a Médicaments contre le sida \|x Aspect social \|z États-Unis \|v Congrès.
650		6	\|a Pharmacologie expérimentale \|x Aspect social \|z États-Unis \|v Congrès.
650		6	\|a Infections à VIH \|x Chimiothérapie \|x Aspect social \|z États-Unis \|v Congrès.
650		6	\|a Comités d'éthique de la recherche.
650		6	\|a Services de santé \|x Accessibilité.
650		6	\|a Contrôle social.
650		6	\|a Sida.
650		6	\|a Enfants.
650		6	\|a Gouvernement fédéral.
650		6	\|a Expérimentation humaine en médecine.
650		6	\|a Sélection de patients.
650		6	\|a Recherche.
650		6	\|a Risque.
650		6	\|a Institutions politiques.
650		6	\|a Infections à VIH.
650		6	\|a Assurance-maladie.
650		6	\|a Évaluation du risque.
650		6	\|a Comités d'éthique.
650		6	\|a Liberté.
650		6	\|a Services d'information.
650		6	\|a Femmes.
650		6	\|a Soins médicaux.
650		6	\|a Consentement éclairé (Droit médical)
650		6	\|a Minorités.
650		6	\|a Industrie pharmaceutique.
650		6	\|a Méthodologie.
650		6	\|a Économie politique.
650		6	\|a Droits de l'homme (Droit international)
650		6	\|a Sociologie.
650		6	\|a Probabilités.
650		6	\|a Industrie.
650		6	\|a Maladies à virus lents.
650		6	\|a Organisations non gouvernementales.
650		6	\|a Prestation de soins.
650		6	\|a Sciences.
650		6	\|a Services de santé.
650		6	\|a Médicaments.
650		6	\|a Services de santé \|x Administration.
650		6	\|a Communication.
650		6	\|a Syndromes de déficit immunitaire.
650		6	\|a Gestion du risque.
650		6	\|a Infections à lentivirus.
650		6	\|a Sciences sociales.
650		6	\|a Assurance.
650		6	\|a Thérapeutique.
650		6	\|a Soins médicaux \|x Qualité \|x Contrôle.
650		6	\|a Statistiques.
650		6	\|a Pratique professionnelle.
650		6	\|a Santé publique.
650		6	\|a Sciences physiques.
650		6	\|a Sciences humaines.
650		6	\|a Infections transmissibles sexuellement.
650		6	\|a Maladies à virus.
650		6	\|a Information.
650		6	\|a Statistique.
650		6	\|a Mésinformation.
650		7	\|a children (people by age group) \|2 aat
650		7	\|a federal government. \|2 aat
650		7	\|a research (function) \|2 aat
650		7	\|a governments (administrative bodies) \|2 aat
650		7	\|a risk assessment. \|2 aat
650		7	\|a freedom. \|2 aat
650		7	\|a minorities. \|2 aat
650		7	\|a methodology. \|2 aat
650		7	\|a economics. \|2 aat
650		7	\|a sociology. \|2 aat
650		7	\|a probability. \|2 aat
650		7	\|a sciences (philosophy) \|2 aat
650		7	\|a risk management. \|2 aat
650		7	\|a social sciences. \|2 aat
650		7	\|a insurance. \|2 aat
650		7	\|a public health. \|2 aat
650		7	\|a physical sciences. \|2 aat
650		7	\|a humanities. \|2 aat
650		7	\|a women (female humans) \|2 aat
650		7	\|a science (modern discipline) \|2 aat
650		7	\|a treating (health care function) \|2 aat
650		7	\|a statistics. \|2 aat
650		7	\|a MEDICAL \|x AIDS & HIV. \|2 bisacsh
650		7	\|a HEALTH & FITNESS \|x Diseases \|x AIDS & HIV. \|2 bisacsh
650		7	\|a Pharmacology, Experimental \|x Social aspects \|2 fast
651		7	\|a United States \|2 fast \|1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq
650		7	\|a Infections à VIH. \|2 fmesh
650		7	\|a Syndrome d'immunodéficience acquise. \|2 fmesh
653		0	\|a AIDS \|a Chemotherapy \|a Social \|a United \|a Congresses
653		0	\|a HIV \|a Chemotherapy \|a Social \|a United \|a Congresses
653		0	\|a Pharmacology, \|a Social \|a United \|a Congresses
655		2	\|a Congress
655		7	\|a proceedings (reports) \|2 aat
655		7	\|a Conference papers and proceedings \|2 fast
655		7	\|a Conference papers and proceedings. \|2 lcgft \|0 http://id.loc.gov/authorities/genreForms/gf2014026068
655		7	\|a Actes de congrès. \|2 rvmgf
710	2		\|a Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine) \|0 http://id.loc.gov/authorities/names/n89230616
776	0	8	\|i Print version: \|a Nichols, Eve K. \|t Expanding access to investigational therapies for HIV infection and AIDS. \|d Washington, D.C. : National Academy Press, 1991 \|z 0309044901 \|w (DLC) 91060585 \|w (OCoLC)23661748
856	4	0	\|l FWS01 \|p ZDB-4-EBA \|q FWS_PDA_EBA \|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14262 \|3 Volltext
938			\|a EBL - Ebook Library \|b EBLB \|n EBL3375988
938			\|a EBSCOhost \|b EBSC \|n 14262
938			\|a YBP Library Services \|b YANK \|n 2309844
938			\|a YBP Library Services \|b YANK \|n 6012552
938			\|a Internet Archive \|b INAR \|n expandingaccesst0000nich
994			\|a 92 \|b GEBAY
912			\|a ZDB-4-EBA
049			\|a DE-863

Datensatz im Suchindex

DE-BY-FWS_katkey	ZDB-4-EBA-ocn559734779
_version_	1816881706560389120
adam_text
any_adam_object
author	Nichols, Eve K.
author_GND	http://id.loc.gov/authorities/names/n86137599
author_corporate	Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine)
author_corporate_role
author_facet	Nichols, Eve K. Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine)
author_role
author_sort	Nichols, Eve K.
author_variant	e k n ek ekn
building	Verbundindex
bvnumber	localFWS
callnumber-first	R - Medicine
callnumber-label	RC607
callnumber-raw	RC607.A26 N53 1991eb
callnumber-search	RC607.A26 N53 1991eb
callnumber-sort	RC 3607 A26 N53 41991EB
callnumber-subject	RC - Internal Medicine
collection	ZDB-4-EBA
contents	""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12â€?13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development"" Improving Response CapabilitiesExpedited Development -- Expanded Access -- Treatment Investigational New Drugs -- Parallel Track -- 2 RIGHTS AND RESPONSIBILITIES -- FREEDOM OF CHOICE -- INFORMED CONSENT -- Information Resources -- Access -- Primary Care -- Difficult Choices -- COMPETING RIGHTS -- INSTITUTIONAL REVIEW BOARDS -- NEW ATTITUDES -- 3 EVALUATION OF EXPANDED ACCESS PROGRAMS -- TREATMENT INVESTIGATIONAL NEW DRUGS -- POTENTIAL RISKS -- Examples from the Past -- The Target Population -- Safety Data IMPACT ON CONVENTIONAL RANDOMIZED TRIALSTHE PARALLEL TRACK EXPERIMENT -- 4 CREATIVITY IN CLINICAL TRIALS -- THE CHANGING ENVIRONMENT -- CONVENTIONAL TRIALS -- PREFERENCE TRIALS -- LARGE, SIMPLE RANDOMIZED TRIALS -- Physician Participation -- Quality Control -- DATA FROM THE PARALLEL TRACK -- Efficacy Data -- Safety Data and Related Information -- Expectations -- 5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY -- TIME TO COMMERCIALIZATION -- DIRECT COSTS OF EXPANDED ACCESS -- Manpower Needs -- Drug Costs -- The Small Manufacturer PRODUCT LIABILITYConcerns Specific to the Parallel Track -- Potential Solutions -- 6 THIRD-PARTY PAYERS -- BLUE CROSS AND BLUE SHIELD -- HEALTH INSURANCE ASSOCIATION OF AMERICA -- HEALTH CARE FINANCING ADMINISTRATION -- Medicaid -- State Discretion -- Patient Care Costs -- Medicare -- RESOURCES FOR CLINICAL INVESTIGATION -- 7 IMPROVING ACCESS TO CARE -- PEOPLE OF COLOR -- Resource Considerations -- Suspicion -- Informed Consent -- WOMEN -- The Gender Perspective -- Risk Factors -- Protocol Development -- Women as Vectors -- A New Approach THE PEDIATRIC POPULATIONScientific Issues -- Social Issues
ctrlnum	(OCoLC)559734779
dewey-full	362.1/969792/00973
dewey-hundreds	300 - Social sciences
dewey-ones	362 - Social problems and services to groups
dewey-raw	362.1/969792/00973
dewey-search	362.1/969792/00973
dewey-sort	3362.1 6969792 3973
dewey-tens	360 - Social problems and services; associations
discipline	Soziologie
format	Electronic eBook
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>18561cam a2203541 a 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn559734779</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cn\|\|\|\|\|\|\|\|\|</controlfield><controlfield tag="008">910211s1991 dcu ob 100 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MERUC</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">MERUC</subfield><subfield code="d">CCO</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UV0</subfield><subfield code="d">CASUM</subfield><subfield code="d">DKDLA</subfield><subfield code="d">OCLCE</subfield><subfield code="d">IDEBK</subfield><subfield code="d">CUS</subfield><subfield code="d">XFF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">ORU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">N$T</subfield><subfield code="d">YDXCP</subfield><subfield code="d">COF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">FVL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">NLGGC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AZK</subfield><subfield code="d">TOA</subfield><subfield code="d">COCUF</subfield><subfield code="d">AGLDB</subfield><subfield code="d">MNU</subfield><subfield code="d">SUR</subfield><subfield code="d">MOR</subfield><subfield code="d">PIFBR</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">U3W</subfield><subfield code="d">OCLCA</subfield><subfield code="d">BUF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">GILDS</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VNS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">LVT</subfield><subfield code="d">VT2</subfield><subfield code="d">STF</subfield><subfield code="d">WRM</subfield><subfield code="d">NRAMU</subfield><subfield code="d">INT</subfield><subfield code="d">XFH</subfield><subfield code="d">EBLCP</subfield><subfield code="d">ZCU</subfield><subfield code="d">ICG</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AU@</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">ADU</subfield><subfield code="d">KIJ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">INARC</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">44954780</subfield><subfield code="a">228064206</subfield><subfield code="a">245535671</subfield><subfield code="a">475709283</subfield><subfield code="a">551505442</subfield><subfield code="a">629930493</subfield><subfield code="a">642456878</subfield><subfield code="a">647353775</subfield><subfield code="a">666933634</subfield><subfield code="a">722242379</subfield><subfield code="a">728013566</subfield><subfield code="a">814274466</subfield><subfield code="a">923259948</subfield><subfield code="a">961669896</subfield><subfield code="a">961673586</subfield><subfield code="a">962592044</subfield><subfield code="a">962635940</subfield><subfield code="a">972040095</subfield><subfield code="a">975242794</subfield><subfield code="a">975293706</subfield><subfield code="a">982314368</subfield><subfield code="a">984884368</subfield><subfield code="a">988438325</subfield><subfield code="a">990088987</subfield><subfield code="a">992114622</subfield><subfield code="a">994555841</subfield><subfield code="a">1003586155</subfield><subfield code="a">1016139292</subfield><subfield code="a">1017678387</subfield><subfield code="a">1018073288</subfield><subfield code="a">1021259647</subfield><subfield code="a">1058117548</subfield><subfield code="a">1112848367</subfield><subfield code="a">1118983063</subfield><subfield code="a">1119024608</subfield><subfield code="a">1156404089</subfield><subfield code="a">1162131089</subfield><subfield code="a">1175669579</subfield><subfield code="a">1182015092</subfield><subfield code="a">1193130606</subfield><subfield code="a">1204385213</subfield><subfield code="a">1228541956</subfield><subfield code="a">1424845104</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">058515547X</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780585155470</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1280203560</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781280203565</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309583367</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309583365</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309044901</subfield><subfield code="q">(pbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309044905</subfield><subfield code="q">(pbk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)559734779</subfield><subfield code="z">(OCoLC)44954780</subfield><subfield code="z">(OCoLC)228064206</subfield><subfield code="z">(OCoLC)245535671</subfield><subfield code="z">(OCoLC)475709283</subfield><subfield code="z">(OCoLC)551505442</subfield><subfield code="z">(OCoLC)629930493</subfield><subfield code="z">(OCoLC)642456878</subfield><subfield code="z">(OCoLC)647353775</subfield><subfield code="z">(OCoLC)666933634</subfield><subfield code="z">(OCoLC)722242379</subfield><subfield code="z">(OCoLC)728013566</subfield><subfield code="z">(OCoLC)814274466</subfield><subfield code="z">(OCoLC)923259948</subfield><subfield code="z">(OCoLC)961669896</subfield><subfield code="z">(OCoLC)961673586</subfield><subfield code="z">(OCoLC)962592044</subfield><subfield code="z">(OCoLC)962635940</subfield><subfield code="z">(OCoLC)972040095</subfield><subfield code="z">(OCoLC)975242794</subfield><subfield code="z">(OCoLC)975293706</subfield><subfield code="z">(OCoLC)982314368</subfield><subfield code="z">(OCoLC)984884368</subfield><subfield code="z">(OCoLC)988438325</subfield><subfield code="z">(OCoLC)990088987</subfield><subfield code="z">(OCoLC)992114622</subfield><subfield code="z">(OCoLC)994555841</subfield><subfield code="z">(OCoLC)1003586155</subfield><subfield code="z">(OCoLC)1016139292</subfield><subfield code="z">(OCoLC)1017678387</subfield><subfield code="z">(OCoLC)1018073288</subfield><subfield code="z">(OCoLC)1021259647</subfield><subfield code="z">(OCoLC)1058117548</subfield><subfield code="z">(OCoLC)1112848367</subfield><subfield code="z">(OCoLC)1118983063</subfield><subfield code="z">(OCoLC)1119024608</subfield><subfield code="z">(OCoLC)1156404089</subfield><subfield code="z">(OCoLC)1162131089</subfield><subfield code="z">(OCoLC)1175669579</subfield><subfield code="z">(OCoLC)1182015092</subfield><subfield code="z">(OCoLC)1193130606</subfield><subfield code="z">(OCoLC)1204385213</subfield><subfield code="z">(OCoLC)1228541956</subfield><subfield code="z">(OCoLC)1424845104</subfield></datafield><datafield tag="042" ind1=" " ind2=" "><subfield code="a">dlr</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC607.A26</subfield><subfield code="b">N53 1991eb</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WD 308</subfield><subfield code="b">N617e 1991</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022020</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039020</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MJCJ2</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">362.1/969792/00973</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bcl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bcl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">GV 90(A1)</subfield><subfield code="2">blsrissc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">HE 66</subfield><subfield code="2">blsrissc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">HE 60</subfield><subfield code="2">blsrissc</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nichols, Eve K.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n86137599</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Expanding access to investigational therapies for HIV infection and AIDS :</subfield><subfield code="b">March 12-13, 1990, conference summary /</subfield><subfield code="c">Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Washington, D.C. :</subfield><subfield code="b">National Academy Press,</subfield><subfield code="c">1991.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (viii, 73 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">data file</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="3">Use copy</subfield><subfield code="f">Restrictions unspecified</subfield><subfield code="5">MiAaHDL</subfield><subfield code="2">star</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="a">Electronic reproduction.</subfield><subfield code="b">[Place of publication not identified] :</subfield><subfield code="c">HathiTrust Digital Library,</subfield><subfield code="d">2010.</subfield><subfield code="5">MiAaHDL</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.</subfield><subfield code="u">http://purl.oclc.org/DLF/benchrepro0212</subfield><subfield code="5">MiAaHDL</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">digitized</subfield><subfield code="c">2010</subfield><subfield code="h">HathiTrust Digital Library</subfield><subfield code="l">committed to preserve</subfield><subfield code="5">MiAaHDL</subfield><subfield code="2">pda</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12â€?13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development""</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Improving Response CapabilitiesExpedited Development -- Expanded Access -- Treatment Investigational New Drugs -- Parallel Track -- 2 RIGHTS AND RESPONSIBILITIES -- FREEDOM OF CHOICE -- INFORMED CONSENT -- Information Resources -- Access -- Primary Care -- Difficult Choices -- COMPETING RIGHTS -- INSTITUTIONAL REVIEW BOARDS -- NEW ATTITUDES -- 3 EVALUATION OF EXPANDED ACCESS PROGRAMS -- TREATMENT INVESTIGATIONAL NEW DRUGS -- POTENTIAL RISKS -- Examples from the Past -- The Target Population -- Safety Data</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">IMPACT ON CONVENTIONAL RANDOMIZED TRIALSTHE PARALLEL TRACK EXPERIMENT -- 4 CREATIVITY IN CLINICAL TRIALS -- THE CHANGING ENVIRONMENT -- CONVENTIONAL TRIALS -- PREFERENCE TRIALS -- LARGE, SIMPLE RANDOMIZED TRIALS -- Physician Participation -- Quality Control -- DATA FROM THE PARALLEL TRACK -- Efficacy Data -- Safety Data and Related Information -- Expectations -- 5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY -- TIME TO COMMERCIALIZATION -- DIRECT COSTS OF EXPANDED ACCESS -- Manpower Needs -- Drug Costs -- The Small Manufacturer</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">PRODUCT LIABILITYConcerns Specific to the Parallel Track -- Potential Solutions -- 6 THIRD-PARTY PAYERS -- BLUE CROSS AND BLUE SHIELD -- HEALTH INSURANCE ASSOCIATION OF AMERICA -- HEALTH CARE FINANCING ADMINISTRATION -- Medicaid -- State Discretion -- Patient Care Costs -- Medicare -- RESOURCES FOR CLINICAL INVESTIGATION -- 7 IMPROVING ACCESS TO CARE -- PEOPLE OF COLOR -- Resource Considerations -- Suspicion -- Informed Consent -- WOMEN -- The Gender Perspective -- Risk Factors -- Protocol Development -- Women as Vectors -- A New Approach</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">THE PEDIATRIC POPULATIONScientific Issues -- Social Issues</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">AIDS (Disease)</subfield><subfield code="x">Chemotherapy</subfield><subfield code="x">Social aspects</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacology, Experimental</subfield><subfield code="x">Social aspects</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">HIV infections</subfield><subfield code="x">Chemotherapy</subfield><subfield code="x">Social aspects</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Institutional review boards (Medicine)</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh2001010894</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Health services accessibility.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh92006496</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Social control.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85123931</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">AIDS (Disease)</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85002541</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Children.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85023418</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Federal government.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85047611</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Human experimentation in medicine.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85062870</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Research.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85113021</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Risk.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85114195</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">HIV infections.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh91004036</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Risk assessment.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh87002638</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Ethics committees.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85045123</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Liberty.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85076480</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Information services.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85066157</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Women.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85147274</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical care.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85082871</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Informed consent (Medical law)</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85066306</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Minorities.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85085792</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85039713</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Methodology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85084414</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Economics.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85040850</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Human rights.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85026379</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Sociology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85124200</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Probabilities.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85107090</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Industries.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85065960</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Slow virus diseases.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85143823</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Non-governmental organizations.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh86007360</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Science.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85118553</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">National health services.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85083180</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85039719</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Health services administration.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85059600</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Communication.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85029027</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Immunological deficiency syndromes.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85064574</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Risk management.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85114200</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Lentivirus infections.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh94005194</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Social sciences.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85124003</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Insurance.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85066802</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Therapeutics.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85134723</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical care</subfield><subfield code="x">Quality control.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85082880</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Statistics.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85127580</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Public health.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85108638</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Physical sciences.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh89005705</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Humanities.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85062913</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Sexually transmitted diseases.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85142634</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Virus diseases.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85143818</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Misinformation.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh2022005564</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Ethics Committees, Research</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Government Regulation</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Health Services Accessibility</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Personal Autonomy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Public Policy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Random Allocation</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Research Design</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Social Control, Formal</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">HIV Seropositivity</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Acquired Immunodeficiency Syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Child</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Federal Government</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Human Experimentation</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Information Dissemination</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Patient Selection</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Research</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Risk</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Socioeconomic Factors</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Government</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">HIV Infections</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Insurance, Health</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Risk Assessment</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Ethics Committees</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Freedom</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Information Services</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Therapeutic Human Experimentation</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Women</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Clinical Trials as Topic</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Patient Care</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Vulnerable Populations</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Informed Consent</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Research Subjects</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Minority Groups</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drugs, Investigational</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Industry</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Financial Support</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Health Care Economics and Organizations</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Methods</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Economics</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Human Rights</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Sociology</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Probability</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Industry</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Principle-Based Ethics</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Slow Virus Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Ethics</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Epidemiologic Study Characteristics as Topic</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Professional Staff Committees</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Organizations</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Evaluation Studies as Topic</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Psychological Phenomena and Processes</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Jurisprudence</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Social Control Policies</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Delivery of Health Care</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Patient Rights</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Science</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Persons</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Health Services</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Epidemiologic Research Design</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Pharmaceutical Preparations</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Patient Care Management</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Population Characteristics</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Communication</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Age Groups</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Sexually Transmitted Diseases, Viral</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Immunologic Deficiency Syndromes</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Risk Management</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Epidemiologic Measurements</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Lentivirus Infections</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Social Sciences</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Information Science</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biomedical Research</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Investigative Techniques</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Therapeutics</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Health Care Quality, Access, and Evaluation</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Quality Assurance, Health Care</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Technology, Industry, and Agriculture</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Statistics as Topic</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Professional Practice</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Public Health</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Natural Science Disciplines</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Health Care Evaluation Mechanisms</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Named Groups</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Financing, Organized</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Humanities</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Sexually Transmitted Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Chemicals and Drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Epidemiologic Methods</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Virus Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Policy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Psychiatry and Psychology</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments contre le sida</subfield><subfield code="x">Aspect social</subfield><subfield code="z">États-Unis</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pharmacologie expérimentale</subfield><subfield code="x">Aspect social</subfield><subfield code="z">États-Unis</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Infections à VIH</subfield><subfield code="x">Chimiothérapie</subfield><subfield code="x">Aspect social</subfield><subfield code="z">États-Unis</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Comités d'éthique de la recherche.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Services de santé</subfield><subfield code="x">Accessibilité.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Contrôle social.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sida.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Enfants.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Gouvernement fédéral.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Expérimentation humaine en médecine.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sélection de patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Recherche.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Risque.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Institutions politiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Infections à VIH.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Assurance-maladie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Évaluation du risque.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Comités d'éthique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Liberté.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Services d'information.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Femmes.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Soins médicaux.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Consentement éclairé (Droit médical)</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Minorités.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Méthodologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Économie politique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Droits de l'homme (Droit international)</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sociologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Probabilités.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Maladies à virus lents.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Organisations non gouvernementales.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Prestation de soins.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sciences.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Services de santé.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Services de santé</subfield><subfield code="x">Administration.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Communication.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Syndromes de déficit immunitaire.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Gestion du risque.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Infections à lentivirus.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sciences sociales.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Assurance.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Thérapeutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Soins médicaux</subfield><subfield code="x">Qualité</subfield><subfield code="x">Contrôle.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Statistiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pratique professionnelle.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Santé publique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sciences physiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sciences humaines.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Infections transmissibles sexuellement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Maladies à virus.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Information.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Statistique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Mésinformation.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">children (people by age group)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">federal government.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">research (function)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">governments (administrative bodies)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">risk assessment.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">freedom.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">minorities.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">methodology.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">economics.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">sociology.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">probability.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">sciences (philosophy)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">risk management.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">social sciences.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">insurance.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">public health.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">physical sciences.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">humanities.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">women (female humans)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">science (modern discipline)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">treating (health care function)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">statistics.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">AIDS & HIV.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">AIDS & HIV.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacology, Experimental</subfield><subfield code="x">Social aspects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Infections à VIH.</subfield><subfield code="2">fmesh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Syndrome d'immunodéficience acquise.</subfield><subfield code="2">fmesh</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">AIDS</subfield><subfield code="a">Chemotherapy</subfield><subfield code="a">Social</subfield><subfield code="a">United</subfield><subfield code="a">Congresses</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">HIV</subfield><subfield code="a">Chemotherapy</subfield><subfield code="a">Social</subfield><subfield code="a">United</subfield><subfield code="a">Congresses</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacology,</subfield><subfield code="a">Social</subfield><subfield code="a">United</subfield><subfield code="a">Congresses</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Congress</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">proceedings (reports)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Conference papers and proceedings</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Conference papers and proceedings.</subfield><subfield code="2">lcgft</subfield><subfield code="0">http://id.loc.gov/authorities/genreForms/gf2014026068</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Actes de congrès.</subfield><subfield code="2">rvmgf</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine)</subfield><subfield code="0">http://id.loc.gov/authorities/names/n89230616</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Nichols, Eve K.</subfield><subfield code="t">Expanding access to investigational therapies for HIV infection and AIDS.</subfield><subfield code="d">Washington, D.C. : National Academy Press, 1991</subfield><subfield code="z">0309044901</subfield><subfield code="w">(DLC) 91060585</subfield><subfield code="w">(OCoLC)23661748</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14262</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL3375988</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">14262</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">2309844</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">6012552</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Internet Archive</subfield><subfield code="b">INAR</subfield><subfield code="n">expandingaccesst0000nich</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection>
genre	Congress proceedings (reports) aat Conference papers and proceedings fast Conference papers and proceedings. lcgft http://id.loc.gov/authorities/genreForms/gf2014026068 Actes de congrès. rvmgf
genre_facet	Congress proceedings (reports) Conference papers and proceedings Conference papers and proceedings. Actes de congrès.
geographic	United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq
geographic_facet	United States
id	ZDB-4-EBA-ocn559734779
illustrated	Not Illustrated
indexdate	2024-11-27T13:16:59Z
institution	BVB
institution_GND	http://id.loc.gov/authorities/names/n89230616
isbn	058515547X 9780585155470
language	English
oclc_num	559734779
open_access_boolean
owner	MAIN DE-863 DE-BY-FWS
owner_facet	MAIN DE-863 DE-BY-FWS
physical	1 online resource (viii, 73 pages)
psigel	ZDB-4-EBA
publishDate	1991
publishDateSearch	1991
publishDateSort	1991
publisher	National Academy Press,
record_format	marc
spelling	Nichols, Eve K. http://id.loc.gov/authorities/names/n86137599 Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary / Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine. Washington, D.C. : National Academy Press, 1991. 1 online resource (viii, 73 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier data file Includes bibliographical references. Print version record. Use copy Restrictions unspecified MiAaHDL star Electronic reproduction. [Place of publication not identified] : HathiTrust Digital Library, 2010. MiAaHDL Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. http://purl.oclc.org/DLF/benchrepro0212 MiAaHDL digitized 2010 HathiTrust Digital Library committed to preserve MiAaHDL pda ""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12â€?13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development"" Improving Response CapabilitiesExpedited Development -- Expanded Access -- Treatment Investigational New Drugs -- Parallel Track -- 2 RIGHTS AND RESPONSIBILITIES -- FREEDOM OF CHOICE -- INFORMED CONSENT -- Information Resources -- Access -- Primary Care -- Difficult Choices -- COMPETING RIGHTS -- INSTITUTIONAL REVIEW BOARDS -- NEW ATTITUDES -- 3 EVALUATION OF EXPANDED ACCESS PROGRAMS -- TREATMENT INVESTIGATIONAL NEW DRUGS -- POTENTIAL RISKS -- Examples from the Past -- The Target Population -- Safety Data IMPACT ON CONVENTIONAL RANDOMIZED TRIALSTHE PARALLEL TRACK EXPERIMENT -- 4 CREATIVITY IN CLINICAL TRIALS -- THE CHANGING ENVIRONMENT -- CONVENTIONAL TRIALS -- PREFERENCE TRIALS -- LARGE, SIMPLE RANDOMIZED TRIALS -- Physician Participation -- Quality Control -- DATA FROM THE PARALLEL TRACK -- Efficacy Data -- Safety Data and Related Information -- Expectations -- 5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY -- TIME TO COMMERCIALIZATION -- DIRECT COSTS OF EXPANDED ACCESS -- Manpower Needs -- Drug Costs -- The Small Manufacturer PRODUCT LIABILITYConcerns Specific to the Parallel Track -- Potential Solutions -- 6 THIRD-PARTY PAYERS -- BLUE CROSS AND BLUE SHIELD -- HEALTH INSURANCE ASSOCIATION OF AMERICA -- HEALTH CARE FINANCING ADMINISTRATION -- Medicaid -- State Discretion -- Patient Care Costs -- Medicare -- RESOURCES FOR CLINICAL INVESTIGATION -- 7 IMPROVING ACCESS TO CARE -- PEOPLE OF COLOR -- Resource Considerations -- Suspicion -- Informed Consent -- WOMEN -- The Gender Perspective -- Risk Factors -- Protocol Development -- Women as Vectors -- A New Approach THE PEDIATRIC POPULATIONScientific Issues -- Social Issues English. AIDS (Disease) Chemotherapy Social aspects United States Congresses. Pharmacology, Experimental Social aspects United States Congresses. HIV infections Chemotherapy Social aspects United States Congresses. Institutional review boards (Medicine) http://id.loc.gov/authorities/subjects/sh2001010894 Health services accessibility. http://id.loc.gov/authorities/subjects/sh92006496 Social control. http://id.loc.gov/authorities/subjects/sh85123931 AIDS (Disease) http://id.loc.gov/authorities/subjects/sh85002541 Children. http://id.loc.gov/authorities/subjects/sh85023418 Federal government. http://id.loc.gov/authorities/subjects/sh85047611 Human experimentation in medicine. http://id.loc.gov/authorities/subjects/sh85062870 Research. http://id.loc.gov/authorities/subjects/sh85113021 Risk. http://id.loc.gov/authorities/subjects/sh85114195 HIV infections. http://id.loc.gov/authorities/subjects/sh91004036 Risk assessment. http://id.loc.gov/authorities/subjects/sh87002638 Ethics committees. http://id.loc.gov/authorities/subjects/sh85045123 Liberty. http://id.loc.gov/authorities/subjects/sh85076480 Information services. http://id.loc.gov/authorities/subjects/sh85066157 Women. http://id.loc.gov/authorities/subjects/sh85147274 Medical care. http://id.loc.gov/authorities/subjects/sh85082871 Informed consent (Medical law) http://id.loc.gov/authorities/subjects/sh85066306 Minorities. http://id.loc.gov/authorities/subjects/sh85085792 Pharmaceutical industry. http://id.loc.gov/authorities/subjects/sh85039713 Methodology. http://id.loc.gov/authorities/subjects/sh85084414 Economics. http://id.loc.gov/authorities/subjects/sh85040850 Human rights. http://id.loc.gov/authorities/subjects/sh85026379 Sociology. http://id.loc.gov/authorities/subjects/sh85124200 Probabilities. http://id.loc.gov/authorities/subjects/sh85107090 Industries. http://id.loc.gov/authorities/subjects/sh85065960 Slow virus diseases. http://id.loc.gov/authorities/subjects/sh85143823 Non-governmental organizations. http://id.loc.gov/authorities/subjects/sh86007360 Science. http://id.loc.gov/authorities/subjects/sh85118553 National health services. http://id.loc.gov/authorities/subjects/sh85083180 Drugs. http://id.loc.gov/authorities/subjects/sh85039719 Health services administration. http://id.loc.gov/authorities/subjects/sh85059600 Communication. http://id.loc.gov/authorities/subjects/sh85029027 Immunological deficiency syndromes. http://id.loc.gov/authorities/subjects/sh85064574 Risk management. http://id.loc.gov/authorities/subjects/sh85114200 Lentivirus infections. http://id.loc.gov/authorities/subjects/sh94005194 Social sciences. http://id.loc.gov/authorities/subjects/sh85124003 Insurance. http://id.loc.gov/authorities/subjects/sh85066802 Therapeutics. http://id.loc.gov/authorities/subjects/sh85134723 Medical care Quality control. http://id.loc.gov/authorities/subjects/sh85082880 Statistics. http://id.loc.gov/authorities/subjects/sh85127580 Public health. http://id.loc.gov/authorities/subjects/sh85108638 Physical sciences. http://id.loc.gov/authorities/subjects/sh89005705 Humanities. http://id.loc.gov/authorities/subjects/sh85062913 Sexually transmitted diseases. http://id.loc.gov/authorities/subjects/sh85142634 Virus diseases. http://id.loc.gov/authorities/subjects/sh85143818 Misinformation. http://id.loc.gov/authorities/subjects/sh2022005564 Ethics Committees, Research Government Regulation Health Services Accessibility Personal Autonomy Public Policy Random Allocation Research Design Social Control, Formal HIV Seropositivity Acquired Immunodeficiency Syndrome Child Federal Government Human Experimentation Information Dissemination Patient Selection Research Risk Socioeconomic Factors Government HIV Infections Insurance, Health Risk Assessment Ethics Committees Freedom Information Services Therapeutic Human Experimentation Women Clinical Trials as Topic Patient Care Vulnerable Populations Informed Consent Research Subjects Minority Groups Drugs, Investigational Drug Industry Financial Support Health Care Economics and Organizations Methods Economics Human Rights Sociology Probability Industry Principle-Based Ethics Slow Virus Diseases Ethics Epidemiologic Study Characteristics as Topic Professional Staff Committees Organizations Evaluation Studies as Topic Psychological Phenomena and Processes Jurisprudence Social Control Policies Delivery of Health Care Patient Rights Science Persons Health Services Epidemiologic Research Design Pharmaceutical Preparations Patient Care Management Population Characteristics Communication Age Groups Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Risk Management Epidemiologic Measurements Lentivirus Infections Social Sciences Information Science Biomedical Research Insurance Investigative Techniques Therapeutics Health Care Quality, Access, and Evaluation Quality Assurance, Health Care Technology, Industry, and Agriculture Statistics as Topic Professional Practice Public Health Natural Science Disciplines Health Care Evaluation Mechanisms Named Groups Financing, Organized Humanities Sexually Transmitted Diseases Chemicals and Drugs Epidemiologic Methods Virus Diseases Policy Psychiatry and Psychology Médicaments contre le sida Aspect social États-Unis Congrès. Pharmacologie expérimentale Aspect social États-Unis Congrès. Infections à VIH Chimiothérapie Aspect social États-Unis Congrès. Comités d'éthique de la recherche. Services de santé Accessibilité. Contrôle social. Sida. Enfants. Gouvernement fédéral. Expérimentation humaine en médecine. Sélection de patients. Recherche. Risque. Institutions politiques. Infections à VIH. Assurance-maladie. Évaluation du risque. Comités d'éthique. Liberté. Services d'information. Femmes. Soins médicaux. Consentement éclairé (Droit médical) Minorités. Industrie pharmaceutique. Méthodologie. Économie politique. Droits de l'homme (Droit international) Sociologie. Probabilités. Industrie. Maladies à virus lents. Organisations non gouvernementales. Prestation de soins. Sciences. Services de santé. Médicaments. Services de santé Administration. Communication. Syndromes de déficit immunitaire. Gestion du risque. Infections à lentivirus. Sciences sociales. Assurance. Thérapeutique. Soins médicaux Qualité Contrôle. Statistiques. Pratique professionnelle. Santé publique. Sciences physiques. Sciences humaines. Infections transmissibles sexuellement. Maladies à virus. Information. Statistique. Mésinformation. children (people by age group) aat federal government. aat research (function) aat governments (administrative bodies) aat risk assessment. aat freedom. aat minorities. aat methodology. aat economics. aat sociology. aat probability. aat sciences (philosophy) aat risk management. aat social sciences. aat insurance. aat public health. aat physical sciences. aat humanities. aat women (female humans) aat science (modern discipline) aat treating (health care function) aat statistics. aat MEDICAL AIDS & HIV. bisacsh HEALTH & FITNESS Diseases AIDS & HIV. bisacsh Pharmacology, Experimental Social aspects fast United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq Infections à VIH. fmesh Syndrome d'immunodéficience acquise. fmesh AIDS Chemotherapy Social United Congresses HIV Chemotherapy Social United Congresses Pharmacology, Social United Congresses Congress proceedings (reports) aat Conference papers and proceedings fast Conference papers and proceedings. lcgft http://id.loc.gov/authorities/genreForms/gf2014026068 Actes de congrès. rvmgf Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine) http://id.loc.gov/authorities/names/n89230616 Print version: Nichols, Eve K. Expanding access to investigational therapies for HIV infection and AIDS. Washington, D.C. : National Academy Press, 1991 0309044901 (DLC) 91060585 (OCoLC)23661748 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14262 Volltext
spellingShingle	Nichols, Eve K. Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary / ""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12â€?13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development"" Improving Response CapabilitiesExpedited Development -- Expanded Access -- Treatment Investigational New Drugs -- Parallel Track -- 2 RIGHTS AND RESPONSIBILITIES -- FREEDOM OF CHOICE -- INFORMED CONSENT -- Information Resources -- Access -- Primary Care -- Difficult Choices -- COMPETING RIGHTS -- INSTITUTIONAL REVIEW BOARDS -- NEW ATTITUDES -- 3 EVALUATION OF EXPANDED ACCESS PROGRAMS -- TREATMENT INVESTIGATIONAL NEW DRUGS -- POTENTIAL RISKS -- Examples from the Past -- The Target Population -- Safety Data IMPACT ON CONVENTIONAL RANDOMIZED TRIALSTHE PARALLEL TRACK EXPERIMENT -- 4 CREATIVITY IN CLINICAL TRIALS -- THE CHANGING ENVIRONMENT -- CONVENTIONAL TRIALS -- PREFERENCE TRIALS -- LARGE, SIMPLE RANDOMIZED TRIALS -- Physician Participation -- Quality Control -- DATA FROM THE PARALLEL TRACK -- Efficacy Data -- Safety Data and Related Information -- Expectations -- 5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY -- TIME TO COMMERCIALIZATION -- DIRECT COSTS OF EXPANDED ACCESS -- Manpower Needs -- Drug Costs -- The Small Manufacturer PRODUCT LIABILITYConcerns Specific to the Parallel Track -- Potential Solutions -- 6 THIRD-PARTY PAYERS -- BLUE CROSS AND BLUE SHIELD -- HEALTH INSURANCE ASSOCIATION OF AMERICA -- HEALTH CARE FINANCING ADMINISTRATION -- Medicaid -- State Discretion -- Patient Care Costs -- Medicare -- RESOURCES FOR CLINICAL INVESTIGATION -- 7 IMPROVING ACCESS TO CARE -- PEOPLE OF COLOR -- Resource Considerations -- Suspicion -- Informed Consent -- WOMEN -- The Gender Perspective -- Risk Factors -- Protocol Development -- Women as Vectors -- A New Approach THE PEDIATRIC POPULATIONScientific Issues -- Social Issues AIDS (Disease) Chemotherapy Social aspects United States Congresses. Pharmacology, Experimental Social aspects United States Congresses. HIV infections Chemotherapy Social aspects United States Congresses. Institutional review boards (Medicine) http://id.loc.gov/authorities/subjects/sh2001010894 Health services accessibility. http://id.loc.gov/authorities/subjects/sh92006496 Social control. http://id.loc.gov/authorities/subjects/sh85123931 AIDS (Disease) http://id.loc.gov/authorities/subjects/sh85002541 Children. http://id.loc.gov/authorities/subjects/sh85023418 Federal government. http://id.loc.gov/authorities/subjects/sh85047611 Human experimentation in medicine. http://id.loc.gov/authorities/subjects/sh85062870 Research. http://id.loc.gov/authorities/subjects/sh85113021 Risk. http://id.loc.gov/authorities/subjects/sh85114195 HIV infections. http://id.loc.gov/authorities/subjects/sh91004036 Risk assessment. http://id.loc.gov/authorities/subjects/sh87002638 Ethics committees. http://id.loc.gov/authorities/subjects/sh85045123 Liberty. http://id.loc.gov/authorities/subjects/sh85076480 Information services. http://id.loc.gov/authorities/subjects/sh85066157 Women. http://id.loc.gov/authorities/subjects/sh85147274 Medical care. http://id.loc.gov/authorities/subjects/sh85082871 Informed consent (Medical law) http://id.loc.gov/authorities/subjects/sh85066306 Minorities. http://id.loc.gov/authorities/subjects/sh85085792 Pharmaceutical industry. http://id.loc.gov/authorities/subjects/sh85039713 Methodology. http://id.loc.gov/authorities/subjects/sh85084414 Economics. http://id.loc.gov/authorities/subjects/sh85040850 Human rights. http://id.loc.gov/authorities/subjects/sh85026379 Sociology. http://id.loc.gov/authorities/subjects/sh85124200 Probabilities. http://id.loc.gov/authorities/subjects/sh85107090 Industries. http://id.loc.gov/authorities/subjects/sh85065960 Slow virus diseases. http://id.loc.gov/authorities/subjects/sh85143823 Non-governmental organizations. http://id.loc.gov/authorities/subjects/sh86007360 Science. http://id.loc.gov/authorities/subjects/sh85118553 National health services. http://id.loc.gov/authorities/subjects/sh85083180 Drugs. http://id.loc.gov/authorities/subjects/sh85039719 Health services administration. http://id.loc.gov/authorities/subjects/sh85059600 Communication. http://id.loc.gov/authorities/subjects/sh85029027 Immunological deficiency syndromes. http://id.loc.gov/authorities/subjects/sh85064574 Risk management. http://id.loc.gov/authorities/subjects/sh85114200 Lentivirus infections. http://id.loc.gov/authorities/subjects/sh94005194 Social sciences. http://id.loc.gov/authorities/subjects/sh85124003 Insurance. http://id.loc.gov/authorities/subjects/sh85066802 Therapeutics. http://id.loc.gov/authorities/subjects/sh85134723 Medical care Quality control. http://id.loc.gov/authorities/subjects/sh85082880 Statistics. http://id.loc.gov/authorities/subjects/sh85127580 Public health. http://id.loc.gov/authorities/subjects/sh85108638 Physical sciences. http://id.loc.gov/authorities/subjects/sh89005705 Humanities. http://id.loc.gov/authorities/subjects/sh85062913 Sexually transmitted diseases. http://id.loc.gov/authorities/subjects/sh85142634 Virus diseases. http://id.loc.gov/authorities/subjects/sh85143818 Misinformation. http://id.loc.gov/authorities/subjects/sh2022005564 Ethics Committees, Research Government Regulation Health Services Accessibility Personal Autonomy Public Policy Random Allocation Research Design Social Control, Formal HIV Seropositivity Acquired Immunodeficiency Syndrome Child Federal Government Human Experimentation Information Dissemination Patient Selection Research Risk Socioeconomic Factors Government HIV Infections Insurance, Health Risk Assessment Ethics Committees Freedom Information Services Therapeutic Human Experimentation Women Clinical Trials as Topic Patient Care Vulnerable Populations Informed Consent Research Subjects Minority Groups Drugs, Investigational Drug Industry Financial Support Health Care Economics and Organizations Methods Economics Human Rights Sociology Probability Industry Principle-Based Ethics Slow Virus Diseases Ethics Epidemiologic Study Characteristics as Topic Professional Staff Committees Organizations Evaluation Studies as Topic Psychological Phenomena and Processes Jurisprudence Social Control Policies Delivery of Health Care Patient Rights Science Persons Health Services Epidemiologic Research Design Pharmaceutical Preparations Patient Care Management Population Characteristics Communication Age Groups Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Risk Management Epidemiologic Measurements Lentivirus Infections Social Sciences Information Science Biomedical Research Insurance Investigative Techniques Therapeutics Health Care Quality, Access, and Evaluation Quality Assurance, Health Care Technology, Industry, and Agriculture Statistics as Topic Professional Practice Public Health Natural Science Disciplines Health Care Evaluation Mechanisms Named Groups Financing, Organized Humanities Sexually Transmitted Diseases Chemicals and Drugs Epidemiologic Methods Virus Diseases Policy Psychiatry and Psychology Médicaments contre le sida Aspect social États-Unis Congrès. Pharmacologie expérimentale Aspect social États-Unis Congrès. Infections à VIH Chimiothérapie Aspect social États-Unis Congrès. Comités d'éthique de la recherche. Services de santé Accessibilité. Contrôle social. Sida. Enfants. Gouvernement fédéral. Expérimentation humaine en médecine. Sélection de patients. Recherche. Risque. Institutions politiques. Infections à VIH. Assurance-maladie. Évaluation du risque. Comités d'éthique. Liberté. Services d'information. Femmes. Soins médicaux. Consentement éclairé (Droit médical) Minorités. Industrie pharmaceutique. Méthodologie. Économie politique. Droits de l'homme (Droit international) Sociologie. Probabilités. Industrie. Maladies à virus lents. Organisations non gouvernementales. Prestation de soins. Sciences. Services de santé. Médicaments. Services de santé Administration. Communication. Syndromes de déficit immunitaire. Gestion du risque. Infections à lentivirus. Sciences sociales. Assurance. Thérapeutique. Soins médicaux Qualité Contrôle. Statistiques. Pratique professionnelle. Santé publique. Sciences physiques. Sciences humaines. Infections transmissibles sexuellement. Maladies à virus. Information. Statistique. Mésinformation. children (people by age group) aat federal government. aat research (function) aat governments (administrative bodies) aat risk assessment. aat freedom. aat minorities. aat methodology. aat economics. aat sociology. aat probability. aat sciences (philosophy) aat risk management. aat social sciences. aat insurance. aat public health. aat physical sciences. aat humanities. aat women (female humans) aat science (modern discipline) aat treating (health care function) aat statistics. aat MEDICAL AIDS & HIV. bisacsh HEALTH & FITNESS Diseases AIDS & HIV. bisacsh Pharmacology, Experimental Social aspects fast Infections à VIH. fmesh Syndrome d'immunodéficience acquise. fmesh
subject_GND	http://id.loc.gov/authorities/subjects/sh2001010894 http://id.loc.gov/authorities/subjects/sh92006496 http://id.loc.gov/authorities/subjects/sh85123931 http://id.loc.gov/authorities/subjects/sh85002541 http://id.loc.gov/authorities/subjects/sh85023418 http://id.loc.gov/authorities/subjects/sh85047611 http://id.loc.gov/authorities/subjects/sh85062870 http://id.loc.gov/authorities/subjects/sh85113021 http://id.loc.gov/authorities/subjects/sh85114195 http://id.loc.gov/authorities/subjects/sh91004036 http://id.loc.gov/authorities/subjects/sh87002638 http://id.loc.gov/authorities/subjects/sh85045123 http://id.loc.gov/authorities/subjects/sh85076480 http://id.loc.gov/authorities/subjects/sh85066157 http://id.loc.gov/authorities/subjects/sh85147274 http://id.loc.gov/authorities/subjects/sh85082871 http://id.loc.gov/authorities/subjects/sh85066306 http://id.loc.gov/authorities/subjects/sh85085792 http://id.loc.gov/authorities/subjects/sh85039713 http://id.loc.gov/authorities/subjects/sh85084414 http://id.loc.gov/authorities/subjects/sh85040850 http://id.loc.gov/authorities/subjects/sh85026379 http://id.loc.gov/authorities/subjects/sh85124200 http://id.loc.gov/authorities/subjects/sh85107090 http://id.loc.gov/authorities/subjects/sh85065960 http://id.loc.gov/authorities/subjects/sh85143823 http://id.loc.gov/authorities/subjects/sh86007360 http://id.loc.gov/authorities/subjects/sh85118553 http://id.loc.gov/authorities/subjects/sh85083180 http://id.loc.gov/authorities/subjects/sh85039719 http://id.loc.gov/authorities/subjects/sh85059600 http://id.loc.gov/authorities/subjects/sh85029027 http://id.loc.gov/authorities/subjects/sh85064574 http://id.loc.gov/authorities/subjects/sh85114200 http://id.loc.gov/authorities/subjects/sh94005194 http://id.loc.gov/authorities/subjects/sh85124003 http://id.loc.gov/authorities/subjects/sh85066802 http://id.loc.gov/authorities/subjects/sh85134723 http://id.loc.gov/authorities/subjects/sh85082880 http://id.loc.gov/authorities/subjects/sh85127580 http://id.loc.gov/authorities/subjects/sh85108638 http://id.loc.gov/authorities/subjects/sh89005705 http://id.loc.gov/authorities/subjects/sh85062913 http://id.loc.gov/authorities/subjects/sh85142634 http://id.loc.gov/authorities/subjects/sh85143818 http://id.loc.gov/authorities/subjects/sh2022005564 http://id.loc.gov/authorities/genreForms/gf2014026068
title	Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary /
title_auth	Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary /
title_exact_search	Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary /
title_full	Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary / Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.
title_fullStr	Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary / Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.
title_full_unstemmed	Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary / Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.
title_short	Expanding access to investigational therapies for HIV infection and AIDS :
title_sort	expanding access to investigational therapies for hiv infection and aids march 12 13 1990 conference summary
title_sub	March 12-13, 1990, conference summary /
topic	AIDS (Disease) Chemotherapy Social aspects United States Congresses. Pharmacology, Experimental Social aspects United States Congresses. HIV infections Chemotherapy Social aspects United States Congresses. Institutional review boards (Medicine) http://id.loc.gov/authorities/subjects/sh2001010894 Health services accessibility. http://id.loc.gov/authorities/subjects/sh92006496 Social control. http://id.loc.gov/authorities/subjects/sh85123931 AIDS (Disease) http://id.loc.gov/authorities/subjects/sh85002541 Children. http://id.loc.gov/authorities/subjects/sh85023418 Federal government. http://id.loc.gov/authorities/subjects/sh85047611 Human experimentation in medicine. http://id.loc.gov/authorities/subjects/sh85062870 Research. http://id.loc.gov/authorities/subjects/sh85113021 Risk. http://id.loc.gov/authorities/subjects/sh85114195 HIV infections. http://id.loc.gov/authorities/subjects/sh91004036 Risk assessment. http://id.loc.gov/authorities/subjects/sh87002638 Ethics committees. http://id.loc.gov/authorities/subjects/sh85045123 Liberty. http://id.loc.gov/authorities/subjects/sh85076480 Information services. http://id.loc.gov/authorities/subjects/sh85066157 Women. http://id.loc.gov/authorities/subjects/sh85147274 Medical care. http://id.loc.gov/authorities/subjects/sh85082871 Informed consent (Medical law) http://id.loc.gov/authorities/subjects/sh85066306 Minorities. http://id.loc.gov/authorities/subjects/sh85085792 Pharmaceutical industry. http://id.loc.gov/authorities/subjects/sh85039713 Methodology. http://id.loc.gov/authorities/subjects/sh85084414 Economics. http://id.loc.gov/authorities/subjects/sh85040850 Human rights. http://id.loc.gov/authorities/subjects/sh85026379 Sociology. http://id.loc.gov/authorities/subjects/sh85124200 Probabilities. http://id.loc.gov/authorities/subjects/sh85107090 Industries. http://id.loc.gov/authorities/subjects/sh85065960 Slow virus diseases. http://id.loc.gov/authorities/subjects/sh85143823 Non-governmental organizations. http://id.loc.gov/authorities/subjects/sh86007360 Science. http://id.loc.gov/authorities/subjects/sh85118553 National health services. http://id.loc.gov/authorities/subjects/sh85083180 Drugs. http://id.loc.gov/authorities/subjects/sh85039719 Health services administration. http://id.loc.gov/authorities/subjects/sh85059600 Communication. http://id.loc.gov/authorities/subjects/sh85029027 Immunological deficiency syndromes. http://id.loc.gov/authorities/subjects/sh85064574 Risk management. http://id.loc.gov/authorities/subjects/sh85114200 Lentivirus infections. http://id.loc.gov/authorities/subjects/sh94005194 Social sciences. http://id.loc.gov/authorities/subjects/sh85124003 Insurance. http://id.loc.gov/authorities/subjects/sh85066802 Therapeutics. http://id.loc.gov/authorities/subjects/sh85134723 Medical care Quality control. http://id.loc.gov/authorities/subjects/sh85082880 Statistics. http://id.loc.gov/authorities/subjects/sh85127580 Public health. http://id.loc.gov/authorities/subjects/sh85108638 Physical sciences. http://id.loc.gov/authorities/subjects/sh89005705 Humanities. http://id.loc.gov/authorities/subjects/sh85062913 Sexually transmitted diseases. http://id.loc.gov/authorities/subjects/sh85142634 Virus diseases. http://id.loc.gov/authorities/subjects/sh85143818 Misinformation. http://id.loc.gov/authorities/subjects/sh2022005564 Ethics Committees, Research Government Regulation Health Services Accessibility Personal Autonomy Public Policy Random Allocation Research Design Social Control, Formal HIV Seropositivity Acquired Immunodeficiency Syndrome Child Federal Government Human Experimentation Information Dissemination Patient Selection Research Risk Socioeconomic Factors Government HIV Infections Insurance, Health Risk Assessment Ethics Committees Freedom Information Services Therapeutic Human Experimentation Women Clinical Trials as Topic Patient Care Vulnerable Populations Informed Consent Research Subjects Minority Groups Drugs, Investigational Drug Industry Financial Support Health Care Economics and Organizations Methods Economics Human Rights Sociology Probability Industry Principle-Based Ethics Slow Virus Diseases Ethics Epidemiologic Study Characteristics as Topic Professional Staff Committees Organizations Evaluation Studies as Topic Psychological Phenomena and Processes Jurisprudence Social Control Policies Delivery of Health Care Patient Rights Science Persons Health Services Epidemiologic Research Design Pharmaceutical Preparations Patient Care Management Population Characteristics Communication Age Groups Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Risk Management Epidemiologic Measurements Lentivirus Infections Social Sciences Information Science Biomedical Research Insurance Investigative Techniques Therapeutics Health Care Quality, Access, and Evaluation Quality Assurance, Health Care Technology, Industry, and Agriculture Statistics as Topic Professional Practice Public Health Natural Science Disciplines Health Care Evaluation Mechanisms Named Groups Financing, Organized Humanities Sexually Transmitted Diseases Chemicals and Drugs Epidemiologic Methods Virus Diseases Policy Psychiatry and Psychology Médicaments contre le sida Aspect social États-Unis Congrès. Pharmacologie expérimentale Aspect social États-Unis Congrès. Infections à VIH Chimiothérapie Aspect social États-Unis Congrès. Comités d'éthique de la recherche. Services de santé Accessibilité. Contrôle social. Sida. Enfants. Gouvernement fédéral. Expérimentation humaine en médecine. Sélection de patients. Recherche. Risque. Institutions politiques. Infections à VIH. Assurance-maladie. Évaluation du risque. Comités d'éthique. Liberté. Services d'information. Femmes. Soins médicaux. Consentement éclairé (Droit médical) Minorités. Industrie pharmaceutique. Méthodologie. Économie politique. Droits de l'homme (Droit international) Sociologie. Probabilités. Industrie. Maladies à virus lents. Organisations non gouvernementales. Prestation de soins. Sciences. Services de santé. Médicaments. Services de santé Administration. Communication. Syndromes de déficit immunitaire. Gestion du risque. Infections à lentivirus. Sciences sociales. Assurance. Thérapeutique. Soins médicaux Qualité Contrôle. Statistiques. Pratique professionnelle. Santé publique. Sciences physiques. Sciences humaines. Infections transmissibles sexuellement. Maladies à virus. Information. Statistique. Mésinformation. children (people by age group) aat federal government. aat research (function) aat governments (administrative bodies) aat risk assessment. aat freedom. aat minorities. aat methodology. aat economics. aat sociology. aat probability. aat sciences (philosophy) aat risk management. aat social sciences. aat insurance. aat public health. aat physical sciences. aat humanities. aat women (female humans) aat science (modern discipline) aat treating (health care function) aat statistics. aat MEDICAL AIDS & HIV. bisacsh HEALTH & FITNESS Diseases AIDS & HIV. bisacsh Pharmacology, Experimental Social aspects fast Infections à VIH. fmesh Syndrome d'immunodéficience acquise. fmesh
topic_facet	AIDS (Disease) Chemotherapy Social aspects United States Congresses. Pharmacology, Experimental Social aspects United States Congresses. HIV infections Chemotherapy Social aspects United States Congresses. Institutional review boards (Medicine) Health services accessibility. Social control. AIDS (Disease) Children. Federal government. Human experimentation in medicine. Research. Risk. HIV infections. Risk assessment. Ethics committees. Liberty. Information services. Women. Medical care. Informed consent (Medical law) Minorities. Pharmaceutical industry. Methodology. Economics. Human rights. Sociology. Probabilities. Industries. Slow virus diseases. Non-governmental organizations. Science. National health services. Drugs. Health services administration. Communication. Immunological deficiency syndromes. Risk management. Lentivirus infections. Social sciences. Insurance. Therapeutics. Medical care Quality control. Statistics. Public health. Physical sciences. Humanities. Sexually transmitted diseases. Virus diseases. Misinformation. Ethics Committees, Research Government Regulation Health Services Accessibility Personal Autonomy Public Policy Random Allocation Research Design Social Control, Formal HIV Seropositivity Acquired Immunodeficiency Syndrome Child Federal Government Human Experimentation Information Dissemination Patient Selection Research Risk Socioeconomic Factors Government HIV Infections Insurance, Health Risk Assessment Ethics Committees Freedom Information Services Therapeutic Human Experimentation Women Clinical Trials as Topic Patient Care Vulnerable Populations Informed Consent Research Subjects Minority Groups Drugs, Investigational Drug Industry Financial Support Health Care Economics and Organizations Methods Economics Human Rights Sociology Probability Industry Principle-Based Ethics Slow Virus Diseases Ethics Epidemiologic Study Characteristics as Topic Professional Staff Committees Organizations Evaluation Studies as Topic Psychological Phenomena and Processes Jurisprudence Social Control Policies Delivery of Health Care Patient Rights Science Persons Health Services Epidemiologic Research Design Pharmaceutical Preparations Patient Care Management Population Characteristics Communication Age Groups Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Risk Management Epidemiologic Measurements Lentivirus Infections Social Sciences Information Science Biomedical Research Insurance Investigative Techniques Therapeutics Health Care Quality, Access, and Evaluation Quality Assurance, Health Care Technology, Industry, and Agriculture Statistics as Topic Professional Practice Public Health Natural Science Disciplines Health Care Evaluation Mechanisms Named Groups Financing, Organized Humanities Sexually Transmitted Diseases Chemicals and Drugs Epidemiologic Methods Virus Diseases Policy Psychiatry and Psychology Médicaments contre le sida Aspect social États-Unis Congrès. Pharmacologie expérimentale Aspect social États-Unis Congrès. Infections à VIH Chimiothérapie Aspect social États-Unis Congrès. Comités d'éthique de la recherche. Services de santé Accessibilité. Contrôle social. Sida. Enfants. Gouvernement fédéral. Expérimentation humaine en médecine. Sélection de patients. Recherche. Risque. Institutions politiques. Infections à VIH. Assurance-maladie. Évaluation du risque. Comités d'éthique. Liberté. Services d'information. Femmes. Soins médicaux. Consentement éclairé (Droit médical) Minorités. Industrie pharmaceutique. Méthodologie. Économie politique. Droits de l'homme (Droit international) Sociologie. Probabilités. Industrie. Maladies à virus lents. Organisations non gouvernementales. Prestation de soins. Sciences. Services de santé. Médicaments. Services de santé Administration. Syndromes de déficit immunitaire. Gestion du risque. Infections à lentivirus. Sciences sociales. Assurance. Thérapeutique. Soins médicaux Qualité Contrôle. Statistiques. Pratique professionnelle. Santé publique. Sciences physiques. Sciences humaines. Infections transmissibles sexuellement. Maladies à virus. Information. Statistique. Mésinformation. children (people by age group) federal government. research (function) governments (administrative bodies) risk assessment. freedom. minorities. methodology. economics. sociology. probability. sciences (philosophy) risk management. social sciences. insurance. public health. physical sciences. humanities. women (female humans) science (modern discipline) treating (health care function) statistics. MEDICAL AIDS & HIV. HEALTH & FITNESS Diseases AIDS & HIV. Pharmacology, Experimental Social aspects United States Syndrome d'immunodéficience acquise. Congress proceedings (reports) Conference papers and proceedings Conference papers and proceedings. Actes de congrès.
url	https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14262
work_keys_str_mv	AT nicholsevek expandingaccesstoinvestigationaltherapiesforhivinfectionandaidsmarch12131990conferencesummary AT roundtableforthedevelopmentofdrugsandvaccinesagainstaidsinstituteofmedicine expandingaccesstoinvestigationaltherapiesforhivinfectionandaidsmarch12131990conferencesummary

Verfügbarkeit

Es ist kein Print-Exemplar vorhanden.

Volltext öffnen

MARC

Datensatz im Suchindex

Es ist kein Print-Exemplar vorhanden.

Ähnliche Einträge